Tirzepatide Reconstitution: Diluent Choice, Concentration Table, and Stability
Reviewed by the VendPeptides Editorial Team. Written from product labeling, the batch certificate of analysis and published literature. Last updated October 2026.
Tirzepatide is a synthetic dual GIP/GLP-1 receptor agonist peptide supplied as a lyophilized powder for laboratory research.
Tirzepatide has been studied in published preclinical and clinical research, including the SURMOUNT-1 phase 3 trial, for metabolic and receptor-signaling investigations.
It is also known by the code name LY3298176 and the brand names Mounjaro and Zepbound, and VendPeptides sells it in single vials of 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, and 60 mg.
This guide covers what Tirzepatide Reconstitution involves, how to calculate concentration by vial size, how to handle the powder safely in the laboratory, and where to buy research-grade vials.
What is Tirzepatide Reconstitution?
Tirzepatide Reconstitution is the laboratory process of adding a measured volume of diluent to a lyophilized Tirzepatide vial so the peptide dissolves into a known concentration.
The result is expressed in mg/mL (or µg/µL), which lets a researcher calculate the exact peptide mass in any measured volume of the resulting solution.
The process uses standard laboratory equipment: a calibrated pipette, bacteriostatic water or another suitable diluent, and a clean vial. For research purposes only. Not for human consumption.
Always confirm the diluent volume and final concentration against the vial label and the batch certificate of analysis (COA), because those documents take priority over any general table.
Tirzepatide Reconstitution, LY3298176 and Mounjaro: are they the same?
Yes. LY3298176 is the research code name for Tirzepatide, and Mounjaro and Zepbound are brand names used for the same molecule.
The CAS number 2023788-19-2 identifies Tirzepatide regardless of which name appears on a vial.
For laboratory purposes, the name on the label matters less than the batch COA, which states identity, purity, and the mass of peptide in the vial.
For research purposes only. Not for human consumption.
What has Tirzepatide Reconstitution been studied for?
Tirzepatide has been studied in published research as a dual GIP/GLP-1 receptor agonist, and the SURMOUNT-1 phase 3 trial reported its effects in adults with obesity.
Reconstitution itself is a laboratory preparation step, not a research endpoint; it is studied only as part of solution preparation and stability work.
Tirzepatide as sold by VendPeptides is not approved for any medical or veterinary purpose and is supplied strictly for in-vitro research.
For research purposes only. Not for human consumption.
For identity and purity data, consult the batch certificate of analysis (COA) supplied with each vial, and for background read the published literature cited at the end of this article.
Tirzepatide Reconstitution and concentration by vial size
Adding 1 mL (1,000 µL) of bacteriostatic water to a 5 mg vial gives 5 mg/mL, and the same math scales across every vial size.
| Vial size | 10-vial kit total | Diluent added | Resulting concentration | µg per µL |
|---|---|---|---|---|
| 5 mg | 50 mg | 1 mL (1,000 µL) | 5 mg/mL | 5 µg/µL |
| 10 mg | 100 mg | 2 mL (2,000 µL) | 5 mg/mL | 5 µg/µL |
| 20 mg | 200 mg | 2 mL (2,000 µL) | 10 mg/mL | 10 µg/µL |
| 30 mg | 300 mg | 3 mL (3,000 µL) | 10 mg/mL | 10 µg/µL |
| 60 mg | 600 mg | 3 mL (3,000 µL) | 20 mg/mL | 20 µg/µL |
The vial label and the batch certificate of analysis (COA) take priority over any table, so verify the stated peptide mass and diluent volume before calculating.
Tirzepatide Reconstitution 10mg vial
Adding 2 mL (2,000 µL) of diluent to a 10 mg vial gives 5 mg/mL, or 5 µg/µL.
A 10-vial kit contains 100 mg of peptide in total, so the same 5 mg/mL concentration applies to each vial if each is reconstituted with 2 mL.
Record the diluent volume, date, and lot number on the vial label, and check the batch COA for the exact fill mass before you calculate.
For research purposes only. Not for human consumption.
Tirzepatide Reconstitution 5mg vial
Adding 1 mL (1,000 µL) of diluent to a 5 mg vial gives 5 mg/mL, or 5 µg/µL.
A 10-vial kit contains 50 mg of peptide in total.
Smaller vials are convenient when a researcher wants a fresh solution with less unused material, but the concentration math is identical to larger vials.
For research purposes only. Not for human consumption.
How long does reconstituted Tirzepatide stay stable?
There is no single stability figure that applies to every Tirzepatide solution; stability depends on diluent, concentration, temperature, and handling.
Published peptide-stability literature and the batch certificate of analysis (COA) are the appropriate references, and the COA may state a recommended storage temperature for the lyophilized powder.
As a general laboratory practice, keep reconstituted solutions refrigerated, protected from light, and free of repeated temperature cycling, and inspect for cloudiness or particulates before use.
For research purposes only. Not for human consumption.
How to handle Tirzepatide safely in the laboratory
- Read the vial label and the batch certificate of analysis (COA) before opening anything.
- Work in a clean, designated area with gloves, a lab coat, and eye protection.
- Wipe the vial stopper and the work surface with an appropriate laboratory disinfectant and let them dry.
- Draw the diluent with a calibrated pipette and add it slowly down the inside wall of the vial to reduce foaming.
- Swirl or roll the vial gently until the powder dissolves completely; do not shake it vigorously.
- Label the reconstituted vial with the compound name, concentration, diluent, date, and your initials.
- Store the solution according to the COA and your laboratory's standard operating procedure, and log the preparation.
Warning: Contamination, unlabeled vials, and non-sterile technique are the main sources of lost or invalid research material, so keep every step documented and every container labeled.
Is Tirzepatide the same as Retatrutide?
No. Tirzepatide is a dual GIP/GLP-1 receptor agonist, while Retatrutide is a triple agonist studied for GIP, GLP-1, and glucagon receptor activity.
They are different molecules with different CAS numbers, different molecular structures, and different research histories.
If your work involves Retatrutide, use the dedicated Retatrutide Reconstitution: Diluent Choice, Concentration Table, and Stability guide rather than applying Tirzepatide figures.
For research purposes only. Not for human consumption.
Is Tirzepatide safe for humans?
No. VendPeptides supplies Tirzepatide for research purposes only, and it is not for human consumption.
The material as sold is not approved for any medical or veterinary purpose, and it is not a finished pharmaceutical product.
FDA guidance on research chemicals and 'not for human consumption' labeling describes the framework under which such materials are supplied.
For research purposes only. Not for human consumption.
Any question about a regulated medicine belongs with a licensed healthcare professional and the official FDA approval information, not with a research vial.
Can Tirzepatide be used for pets or animals?
No. Tirzepatide from VendPeptides is for research purposes only and is not a veterinary product.
It is not approved for any medical or veterinary purpose, and it must not be given to animals outside an approved research protocol.
For any animal health question, consult a licensed veterinarian.
For research purposes only. Not for human consumption.
Where to buy Tirzepatide (5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg)
VendPeptides sells Tirzepatide as a single-vial research product in 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, and 60 mg strengths, with 10-vial kit totals from 50 mg to 600 mg.
Every vial ships from our US warehouse with a batch certificate of analysis (COA) and an expiry date on the label, and the label takes priority over any published table.
Order the Tirzepatide Single Vial directly, or browse the full Metabolic Research Peptides collection.
Researchers who also work with repair-pathway peptides can add BPC-157, available as 5 mg vials, 10 mg vials, and 5 mg or 10 mg kits.
For current catalogue news, see the Research Peptide Roundup: October 2026: New Publications, Regulatory Updates, and Catalogue Changes, and for a vial-specific walkthrough see Tirzepatide 20mg Vial: Specifications, Reconstitution, and Storage.
For research purposes only. Not for human consumption.
Frequently asked questions
Is Tirzepatide safe for humans?
No. It is supplied for research purposes only and is not for human consumption. The material as sold is not approved for any medical or veterinary purpose.
Is Tirzepatide the same as Retatrutide?
No. Tirzepatide is a dual GIP/GLP-1 receptor agonist, while Retatrutide is a triple agonist studied for GIP, GLP-1, and glucagon receptor activity. They are distinct molecules with different CAS numbers.
What is Tirzepatide Reconstitution for a 10mg vial?
Adding 2 mL (2,000 µL) of diluent to a 10 mg vial gives 5 mg/mL, or 5 µg/µL. Confirm the fill mass on the batch certificate of analysis (COA) before calculating.
Can Tirzepatide be used for pets or animals?
No. It is a research-use-only material, not a veterinary product, and it is not approved for any medical or veterinary purpose. Consult a licensed veterinarian for any animal health question.
Is Tirzepatide the same as Mounjaro or Zepbound?
The molecule is the same, but the names refer to different contexts: Mounjaro and Zepbound are brand names, while VendPeptides supplies Tirzepatide as a research chemical. The vial label and COA define what you actually have.
Is Tirzepatide a peptide, and what class is it?
Yes, Tirzepatide is a synthetic peptide and is classified as a dual GIP/GLP-1 receptor agonist. Its CAS number is 2023788-19-2.
Can you still buy Tirzepatide?
Yes, VendPeptides lists Tirzepatide as a single-vial research product in 5 mg through 60 mg strengths, shipped from a US warehouse with a batch COA. It remains for research purposes only and not for human consumption.
Sources and further reading
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM 2022.
- FDA — Mounjaro (tirzepatide) approval information
- PubChem — Tirzepatide
Disclaimer. This article is educational and describes laboratory handling and published literature only. It is not medical or veterinary advice and is not a substitute for a licensed professional. For research purposes only. Not for human consumption. Products are sold to qualified researchers for in-vitro and laboratory research, are not approved drugs, foods, cosmetics or devices, and are not for human or animal use. This article was written with AI assistance and reviewed by a member of the VendPeptides Editorial Team.